The tweet was deleted by the author.
But we saved everything 🙂.
Syndax Pharmaceuticals has announced a strategic collaboration with the World Orphan Drug Alliance (WODA) to enhance the availability of Revuforj® (revumenib) through a Managed Access Program.
This partnership aims to provide a clear route for patients to access Revuforj in areas where the drug might not be obtainable otherwise. Such initiatives are vital as they address the challenges of accessibility for innovative treatments in underserved regions. Patients and healthcare providers are expected to benefit significantly from this collaboration, as it bridges gaps in healthcare distribution and offers a potential lifeline for those in need.